Predictors of Coronavirus Disease 2019 Hospitalization After Sotrovimab in Patients With Hematologic Malignancy During the BA.1 Omicron Surge.

Judy Yan,Samantha N Steiger,Rich Kodama,Jerome Fender, Carrie Tan,Justin Laracy,Nina Cohen,Tracy McMillen,Krupa Jani,Elizabeth V Robilotti,N Esther Babady,Susan K Seo,Mini Kamboj

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2023）

引用 1|浏览6

暂无评分

摘要

While sotrovimab is effective at reducing COVID-19 hospitalization and disease severity in patients with hematologic malignancy when administered early, patients who received anti-CD20 antibodies showed substantial morbidity. Due to the high potential for resistance mutation to sotrovimab and increased morbidity in patients on anti-CD20 therapy, combination treatment should be explored to determine whether it provides added benefits compared to monotherapy.

查看译文

关键词

COVID-19,SARS-CoV-2,hematologic malignancy,monoclonal antibodies

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要